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INTRODUCTION
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal
dominant myopathy characterized by progressive atrophy of the
facial, shoulder and upper arm muscles. In addition to the muscular
dystrophy, 50-75% of FSHD patients have retinal vasculature
abnormalities (Fitzsimons et al., 1987; Padberg et al., 1995b), and
the upregulation of vasculature system genes is an early event in
FSHD muscle pathology (Osborne et al., 2007). Recently, muscle
biopsies from FSHD patients revealed that the mesoangioblasts,
an adult myogenic mesodermal stem cell occupying the
perivascular niche in muscle tissue, were impaired in their ability
to differentiate into skeletal muscle (Morosetti et al., 2007). Thus,
FSHD progression and pathology, although predominantly evident
in skeletal muscle, probably have underlying contributing or causal
factors that are associated with the vasculature.
The FSHD genetic lesion is a contraction of the tandem array
of 3.3 kb D4Z4 repeats at chromosome 4q35 to below a threshold
of 11 copies (Lunt et al., 1995; Wijmenga et al., 1992). This repeat
contraction is hypothesized to affect the expression of
neighboring gene(s). Based on analysis of gene expression and
proximity to the D4Z4 repeats, FRG1 (FSHD region gene 1), which
is located 100 kb centromeric to the contracted D4Z4 region, is
a leading candidate disease gene for FSHD (van Deutekom et al.,
1996). Since FSHD prominently affects voluntary muscles, studies
on FRG1 have mainly focused on its role in muscles. Previous
work found that FRG1 expression is crucial to the formation of
normal muscle structure and that overexpression of the FRG1
protein adversely affects muscles during development (Hanel et
al., 2009). Similarly, transgenic mice with a 25–40-fold increase
in FRG1 expression, specifically in the skeletal muscle, develop a
dystrophic muscle phenotype (Gabellini et al., 2006). However,
measurements of FRG1 mRNA levels from the muscles of FSHD
patients have varied, including a 25-fold increase in expression,
unchanged expression and a 5-fold decrease in expression, when
compared with control muscles (van Deutekom et al., 1996;
Gabellini et al., 2002; Jiang et al., 2003; Winokur et al., 2003;
Osborne et al., 2007). Thus, a correlation between FRG1 mRNA
levels in skeletal muscle and FSHD pathology remains
inconclusive and controversial.
The protein encoded by the FRG1 gene at chromosome 4q35 in
humans is highly conserved in vertebrates and invertebrates [97%
amino acid (a.a.) identity with the mouse, 81% a.a. identity with X.
laevis and 46% a.a. identity with C. elegans] (Grewal et al., 1998).
FRG1 expression has been detected in all human tissues that have
been tested, including human embryonic brain and muscle, as well
as the placenta (van Deutekom et al., 1996), suggesting that it has
functions outside of the muscle. Here, we show prominent
expression of FRG1 in vascular tissues during Xenopus
development and in adult frog muscle capillaries. Knockdown of
FRG1 results in decreased angiogenesis and loss of the Xenopus
vascular marker DAB2. Overexpression of the FRG1 protein
resulted in an opposite phenotype of increased angiogenesis and
dilated blood vessels. Identifying FRG1 as a mediator of
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SUMMARY
The genetic lesion that is diagnostic for facioscapulohumeral muscular dystrophy (FSHD) results in an epigenetic misregulation of gene expression,
which ultimately leads to the disease pathology. FRG1 (FSHD region gene 1) is a leading candidate for a gene whose misexpression might lead to
FSHD. Because FSHD pathology is most prominent in the musculature, most research and therapy efforts focus on muscle cells. Previously, using
Xenopus development as a model, we showed that altering frg1 expression levels systemically leads to aberrant muscle development, illustrating
the potential for aberrant FRG1 levels to disrupt the musculature. However, 50-75% of FSHD patients also exhibit retinal vasculopathy and FSHD
muscles have increased levels of vascular- and endothelial-related FRG1 transcripts, illustrating an underlying vascular component to the disease.
To date, no FSHD candidate gene has been proposed to affect the vasculature. Here, we focus on a role for FRG1 expression in the vasculature. We
found that endogenous frg1 is expressed in both the developing and adult vasculature in Xenopus. Furthermore, expression of FRG1 was found to
be essential for the development of the vasculature, as a knockdown of FRG1 resulted in decreased angiogenesis and reduced expression of the
angiogenic regulator DAB2. Conversely, tadpoles subjected to frg1 overexpression displayed the pro-angiogenic phenotypes of increased blood
vessel branching and dilation of blood vessels, and developed edemas, suggesting that their circulation was disrupted. Thus, the systemic upregulation
of the FRG1 protein shows the potential for acquiring a disrupted vascular phenotype, providing the first link between a FSHD candidate gene and
the vascular component of FSHD pathology. Overall, in conjunction with our previous analysis, we show that FRG1 overexpression is capable of
disrupting both the musculature and vasculature, recapitulating the two most prominent features of FSHD.
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angiogenesis provides insights into the mechanisms of FSHD
disease pathology and further supports the FRG1 overexpression
disease model for FSHD.
RESULTS
FRG1 is expressed in vascular tissues
Two of the prominent pathological effects in FSHD patients are
the progressive appearance of dystrophic skeletal muscle and
retinal vasculopathy. Previously, we analyzed FRG1 expression in
X. laevis during early development of the musculature (Hanel et
al., 2009). Here, we analyze the X. laevis vasculature to address any
potential vascular role for FRG1. Embryos that were sectioned,
either sagitally or transversely, and immunostained for FRG1 (Fig.
1A) show significant FRG1 expression within the pronephrous (Fig.
1B,C), posterior cardinal vein and arteries (Fig. 1C), indicating that
FRG1 is in fact expressed in the vasculature. However, ubiquitous
levels of frg1 transcripts from maternal stores, which progressively
decrease during development, potentially introduce an elevated
non-tissue-specific background that is not indicative of de novo
expression (Hanel et al., 2009).
A transgenic approach was used in order to determine the tissues
in which active frg1 expression was taking place. The proximal frg1
promoter sequence from X. tropicalis, consisting of a 645 base pair
(bp) upstream regulatory region and 636 bps of the transcribed 5
untranslated region (UTR), was inserted upstream of EGFP
(enhanced green fluorescent protein) into a transgene cassette that
was flanked by chicken β-globin insulator [hypersensitive site 4
(HS4)] doublets (Fig. 1D) and used for transgenesis. This proximal
promoter construct produced a consistent expression pattern in
transgenic animals (61% of transgenic tadpoles, n=44), which was
visualized by fluorescence (Fig. 1E), with 16% displaying an
underlying identical pattern with additional non-uniform spotted
expression and 23% showing variable small patches of expression.
Overall, the predominant pattern of fluorescence that we observed
suggested that promoter expression was heaviest within the eye,
dorsal-anterior portion of the head, branchial arches, and at the
dorsal and ventral portions of the somites. As EGFP is known for
its stability, de novo transcript levels were more clearly examined
by in situ hybridization using an egfp probe. When examined in
this manner, egfp expression in transgenic embryos coincided
largely with fluorescence at stage 32 (Fig. 1E,F). However, as the
tadpoles developed, egfp expression became more confined to
vascular and muscle tissues (Fig. 1G,H). By stage 42, when much
of larval organogenesis is complete, transgenic egfp expression was
predominantly vascular, with weak staining throughout the epaxial
tail muscle and around the gut (Fig. 1H). Although potentially
missing some regulatory elements, the ability of a 645 bp regulatory
region of frg1 to direct gene expression specifically within vascular
tissues strongly supports a role for frg1 in vascular development.
The expression of the FRG1 protein was characterized further
after metamorphosis in cross sections of adult frog gastrocnemius
muscle. FRG1 immunostaining showed strong expression in cells
at the periphery of muscle fibers (Fig. 1I). This staining pattern
shows that FRG1 co-localizes with the capillary marker lectin
dmm.biologists.org268
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Fig. 1. Expression of the FRG1 protein during development.
(A) Stage 36 whole-mount immunostaining shows the ubiquitous
appearance of the FRG1 protein. FRG1-immunostained tadpoles
were then sectioned either sagitally (B) or transversally (C) in the
regions depicted in A. (D) Diagram of the minimal frg1 regulatory
element (FRE) construct that was used to examine tissues with
active transcription. EGFP expression was observed in stage 32
transgenic animals by both whole-mount fluorescence (E) and egfp
in situ hybridization (F). By stage 36, transgenic egfp expression
becomes restricted to muscle and vascular cell lineages (G), and by
stage 42 it is observed almost exclusively within the vasculature (H).
In adult X. laevis, immunostaining of FRG1 [green (I,K)] is observed in
the gastrocnemius muscle, where it colocalizes precisely with
rhodamine-labled lectin [red (J,K)], a marker for capillaries. Antibody
specificity for the FRG1 peptide in these immunohistology
experiments was confirmed by immunostaining with (M), or without
(L), FRG1 peptide competition. (N) Strong FRG1 staining (red) was
observed in arteries and veins in gastrocnemious sections co-
stained with wheat germ agglutinin (green) and DAPI (blue).
Abbreviations: ps, pronephric sinus; pd, pronephric duct; pcv,
posterior cardinal vein; pda, paired dorsal arteries; nc, notochord; nt,
neural tube; aa, aortic arches; ov, ophthalmic vessel; da, dorsal
artery; dlav, dorsal lateral vein. Bars, 1 mm (A,E-H); 30 μm (B,C);
50 μm (K-N).
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(Christie and Thomson, 1989), demonstrating that the FRG1
protein is associated with capillaries within frog muscle (Fig. 1J,K).
Beyond the capillaries, FRG1 was also strongly expressed in froglet
arteries and veins (Fig. 1N). To ensure the specificity of the
antibody, peptide competition with the antigenic peptide was
performed and resulted in an absence of FRG1 staining (Fig. 1L,M).
Control slides, in which the FRG1 primary antibody was omitted,
were consistently negative (data not shown). Thus, similar to stage
42 transgenic tadpoles, the strongest expression of FRG1 within
frog muscle is associated with the vasculature.
FRG1 is required for complete angiogenesis and expression of the
vascular marker DAB2
To determine if FRG1 is required for vasculature development,
FRG1 levels were reduced by specific morpholino (MO) injection.
One cell from each 2-cell stage embryo was injected with an frg1
morpholino (FMO1), which has previously been reported to
adversely affect muscle development (Hanel et al., 2009), or with
a non-specific control morpholino (CMO). Embryos were then
examined at stage 34-36 by whole-mount in situ hybridization for
dab2, which encodes a vascular marker that acts as an angiogenic
regulator, required for sprouting of intersomitic veins (Cheong et
al., 2006). FMO1-injected embryos showed a marked, dose-
dependent reduction in dab2 transcript levels (40 ng of FMO1:
100% reduction, n=42; 20 ng of FMO1: 76% reduction, n=38); the
embryos were scored based on overall dab2 expression in the areas
with the clearest dab2 signal, namely the pronephric sinus, posterial
cardinal vein and vascular vitelline network (Fig. 2A-F,M). In the
embryos with milder phenotypes, fewer branches of the vascular
vitelline network were visible. In many embryos, this reduction was
severe enough to result in a complete loss of dab2 in the vascular
vitelline network and, strikingly, from the intensely stained
pronephric sinus (Fig. 2B,E). Although a small number of CMO-
injected embryos displayed a mild reduction in dab2 staining on
the injected side (26% reduction, n=42), these embryos did not
display the acute loss of dab2 that was seen in FRG1 morphants
(Fig. 2C,F). In addition, dab2 loss was specific to FMO1 knockdown
of FRG1 because dab2 expression levels and patterns were
successfully rescued by co-injection of FMO1 with a non-
complementary mRNA encoding the X. tropicalis FRG1 protein
(Fig. 2H,I,K,L,N).
To determine whether FRG1 knockdown led to a general loss of
vasculature and, thus, of all vascular transcripts, or whether this
effect was more specific to the transcript encoding FRG1, in situ
hybridization was performed on FMO1 morphants for msr, which
encodes an early vascular marker and which can be used to identify
vascular endothelial cells (Devic et al., 1996). Interestingly,
morphant embryo halves did not display an acute loss of msr
transcripts, as levels within the posterior cardinal vein were
comparable to those in the non-injected control half of the embryo.
However, FMO1 injection was observed to cause either partial or
complete (20 ng of FMO1: 76% reduction, n=21; 40 ng of FMO1:
75% reduction, n=12) inhibition of intersomitic vein sprouting (Fig.
2G,J) compared with background levels (40 ng of CMO: 18%
reduction, n=27). The maintenance of the posterior cardinal vein
and lack of intersomitic vein sprouting indicated that, unlike
vasculogenesis, angiogenesis is disrupted by FRG1 knockdown.
Together, these data suggest that FRG1 is required for the
establishment of the intact vasculature, specifically in angiogenic
branching from existing vessels.
Overexpression of the FRG1 protein increases vasculature levels
and angiogenesis
FSHD has been associated previously with elevated levels of FRG1
(Gabellini et al., 2002); therefore, the effects of overexpression of
the FRG1 protein were examined. Systemic levels of FRG1 were
increased through mRNA injections using the X. tropicalis frg1
mRNA, co-injected with a tracer mRNA. These FRG1-
overexpressing embryos were compared with embryos that had
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Fig. 2. Depletion of FRG1 inhibits vascular development. The mild (A) and
severe (B) phenotypes of the FMO1-injected (40 ng) embryos show a
reduction in vascular structures compared with the uninjected sides of the
same embryos (D,E), as visualized by dab2 expression. (C,F) CMO-injected and
uninjected sides of the same embryo, respectively. (G,J) FMO1-injected (40 ng)
and uninjected sides of the same embryo, stained for msr. The arrowheads
point to intersomitic veins. (H,I) Partial and full rescue of dab2 staining by co-
injection with 40 ng of FMO1 and 500 pg of X. tropicalis frg1 mRNA. Co-
injection of 40 ng of FMO1 with 1 ng of X. tropicalis frg1 mRNA was lethal.
(M) The percentage of injected embryos displaying loss of dab2 and msr
staining. (N) The percentage of embryos rescued by co-injection of FMO1 with
frg1 mRNA. The numbers above the bars indicate the total number of embryos
analyzed. Abbreviations: ps, pronephric sinus; vvn, vitelline vein network; pcv,
posterior cardinal vein. Bars, 0.5 mm.
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been injected with tracer mRNA alone. The vasculature of embryos
injected at stage 34-36 was analyzed using in situ hybridization with
either dab2 or msr probes. Both msr and dab2 staining of frg1-
injected embryos displayed abnormally branched (compare Fig. 3A
with Fig. 3B) and dilated posterior cardinal veins (compare Fig.
3A,C,E with Fig. 3B,D,F, respectively). Elevated FRG1 levels led to
similar effects within the intersomitic veins, with increased
branching (Fig. 3E,G) and dilation (Fig. 3C). Errors in vascular
development were observed in 43% and 62% of embryos injected
with 500 pg and 1 ng of frg1, respectively, as analyzed by dab2
expression, and in 64% and 75% of embryos injected with 500 pg
and 1 ng of frg1, respectively, as analyzed by probing for msr.
Intersomitic veins were labeled more prominently by the msr probe
than the dab2 probe, a difference that probably accounts for the
elevated level of observed abnormalities in embryos stained for msr.
In tracer mRNA controls, a similar, but low, level of background
defects was observed following use of the dab2 (10%, n=49) and
msr (10%, n=41) probes. Thus, elevated frg1 levels led to dilated
and overly branched vasculature. Together, this pro-angiogenic
effect of increased FRG1, combined with the decreased
angiogenesis in FRG1 knockdown animals, demonstrates that
FRG1 levels are crucial for the proper regulation of angiogenesis.
Expression of the frg1 transgene leads to edemas and vascular
abnormalities
To analyze the vascular defects associated with consistent and
tissue-specific elevations in FRG1 levels, transgenic animals that
overexpress frg1 from the frg1 proximal promoter (FRE-FRG1) were
generated and were analyzed for vascular abnormalities. The FRE-
FRG1 expression cassette was flanked by HS4 and the Drosophila
Fab8 insulator sequences in order to maintain frg1 expression upon
genome integration. At stage 34, tadpoles were separated into either
transgenic or non-transgenic groups based on expression of gamma
crystalline-GFP within the eye. Upon examination of the embryos
at stage 46, an increased number of tadpoles had developed ventral
edema (Fig. 4B), a phenotype associated with lymphatic system
defects or vascular defects (Inui et al., 2006; Rodrigues et al., 2008).
Although background levels of this phenotype were 18% (n=37) for
non-transgenic sperm recipients, more than a two-fold increase in
this phenotype was observed in the transgenic tadpoles (44%, n=32).
Animals from both transgenic and non-transgenic pools that
appeared normal at stage 46-48 were examined for vascular defects
in the tail by using fluorescein-labeled dextran injections into the
heart. Animals were examined exclusively for gross vascular
abnormalities, which we found to be double branching of the dorsal
lateral vein (compare Fig. 4D with Fig. 4E). A two-fold increase in
these defects was observed in transgenic animals (45%, n=20)
compared with the background levels in non-transgenic animals
(22%, n=22). These results confirm that elevated expression of FRG1
within the vascular tissues, where FRG1 is endogenously expressed,
is capable of producing significant developmental vascular defects.
DISCUSSION
Epigenetic disregulation leading to the overexpression of FRG1 has
been a leading candidate for the mechanism that mediates FSHD
pathology; however, all of the previous studies have focused on
muscle expression, muscle biopsies and muscle cell culture. Here,
a role for FRG1 in the development of vascular structures has been
uncovered. We find that an elevated level of FRG1 not only disrupts
skeletal muscle (Hanel et al., 2009), consistent with previous work
in a mouse model for FSHD (Gabellini et al., 2006), but also leads
to an increase in the size and branching of the vasculature structure;
both of these results are consistent with data from the tissues of
FSHD patients. The vascular component of FSHD has been
described in the retina of the eye where the vasculature can be
readily visualized; however, the upregulation of gene transcripts in
the muscle biopsies from the vascular smooth muscle and
endothelial cells (Osborne et al., 2007) imply a more systemic
disruption of vasculature in FSHD. One benefit of using Xenopus
development for these studies is the ability to visualize intact
vascular structures throughout the body and determine the
systemic effects of altered FRG1 levels. Our analysis of the eye
vasculature was somewhat hindered in the tadpoles that
overexpress the FRG1 protein, owing to the more complex nature
of the vasculature in the ocular region, which made it difficult to
visualize disruption of the architecture. However, consistent with
the results from elsewhere in the body, dab2 expression was clearly
reduced in the eyes of embryos injected with FMO1 (supplementary
material Fig. S1), suggesting that the eye vasculature is similarly
regulated. Thus, the frg1 overexpression phenotype in Xenopus
correlates strongly with both the afflicted tissues and the clinical
dmm.biologists.org270
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Fig. 3. Embryos with elevated FRG1 levels have increased angiogenesis
and vascular dilation. (A-G) Stage 36 tadpoles injected with 500 pg of frg1 on
one side of the embryo were analyzed for vascular abnormalities by using in
situ hybridization to detect dab2 (A-D) or msr (E-G) transcripts. Abnormalities
included branching of the posterior cardinal vein (black arrowhead in A),
dilation of the posterior cardinal vein (black arrowheads in A,C,E), dilation of
intersomitic veins (black arrows in C), and improper growth and branching of
intersomitic veins (black arrows in E,G). For comparison, the uninjected sides
of the embryos from A,C,E are shown in B,D,F, respectively. (H) Numbers of
tadpole embryos displaying vascular abnormalities after injection with 500 pg
of frg1, 1 ng of frg1 and tracer alone. The numbers above the bars indicate the
total numbers of embryos analyzed. Bars, 0.5 mm.
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findings from FSHD patients, consisting of dystrophic muscle with
a variable fiber size, retinal vasculopathy, and misregulation of gene
transcription in the vascular smooth muscle and endothelial tissues
(Fitzsimons et al., 1987; Padberg et al., 1995b; Padberg et al., 1995a;
Osborne et al., 2007).
The finding that FRG1 mediates angiogenesis and not
vasculogenesis was deduced from the maintenance of the posterior
cardinal vein and loss of intersomitic vein sprouting in FRG1
morphants. In agreement, the opposite effect, overbranching of
vascular structures, was observed in animals with elevated levels
of FRG1. Similar to our FMO1 injection experiments, the reduction
of DAB2 in Xenopus led to an inhibition of intersomitic vein
sprouting through the loss of vascular endothelial growth factor
(VEGF) induction (Cheong et al., 2006). It is possible that the loss
of intersomitic sprouting in the FRG1 depletion experiments
occurs as a direct consequence of the reduction in DAB2. However,
FRG1 is probably not a direct regulator of dab2, as elevated levels
of FRG1 did not appear to lead to increased levels of dab2 staining.
Furthermore, whereas overexpression of DAB2 led to a lack of
intersomitic vein sprouting (Cheong et al., 2006), elevated levels of
FRG1 led to improper branching and dilation of the vasculature.
In fact, overexpression of the FRG1 protein in the intersomitic veins
more closely resembles the effects of misexpression of ephB4, which
encodes an ephrin receptor that is part of a second pro-angiogenic
pathway involving ephrins, which are also involved in somitogenesis
(Helbling et al., 2000). Our study indicates that, beyond maintaining
dab2 transcript levels, FRG1 is functioning as a pro-angiogenic
factor.
The maintenance of dab2 transcript levels by FRG1 may affect
many tissues beyond the vasculature. DAB2 is highly expressed in
many adult mammalian tissues and is most commonly known as
a mediator of clathrin-associated endocytosis (Oleinikov et al., 2000;
Kowanetz et al., 2003) and a key component of the transforming
growth factor (TGF)-β signaling pathway. As a component of this
signaling pathway, DAB2 has many functions including roles as a
tumor suppressor (Fazili et al., 1999), a mediator of epithelial-to-
mesenchymal transition (EMT) (Prunier and Howe, 2005), and in
cellular migration (Hocevar et al., 2005). Furthermore, DAB2 is also
involved in the inhibition of Wnt-stimulated cellular proliferation
through its association with Axin (Hocevar et al., 2003; Jiang et al.,
2007). In the vasculature, DAB2 functions in endodermal
organization, differentiation (Morris et al., 2002; Yang et al., 2002)
and in early angiogenesis through induction of VEGF by activin-
like signaling (Cheong et al., 2006). Therefore, FRG1 expression is
crucial for a wide variety of functions simply by its maintenance
of DAB2.
A role for overexpression of the FRG1 protein in FSHD is still
controversial, partly because of inconsistencies between gene
expression studies in cell lines and FSHD muscle, the lack of
information on the precise function of FRG1, and recent studies
supporting potential roles for alternative candidate genes. Our
studies strongly suggest that misexpression of the FRG1 protein is
capable of producing both the musculature and vasculature
pathology seen in FSHD (Hanel et al., 2009). In addition, our data
are consistent with the disrupted cell signaling pathway model for
FSHD that is based primarily on extending the clinical observations
of FSHD patient pathology to diseases of known cause that exhibit
similar pathology. Coats’ disease is caused by a mutation in Norrin,
a ligand to the Wnt receptor Frizzled-4 (Zerlin et al., 2008) and
exhibits retinal vascular abnormalities that are highly similar to
those found in FSHD. The symptoms of FSHD and Coats’ disease
both include the appearance of thick tortuous vessels within the
retina, similar to the vessels found in this study with overexpression
of FRG1. Frizzled-4 mutations, which are linked to familial
exudative vitreoretinopathy, lead to similar retinal vasculopathy
along with progressive auditory defects (Zerlin et al., 2008), a
symptom that has also been associated with FSHD. Thus, owing
to these similarities between FSHD and Coats’ disease, FSHD is
speculated to involve a defect in the Wnt signaling pathway, a
mechanism that is supported by our data.
Conclusions
In summary, our study has shown that FRG1 is expressed in
vascular structures and is essential for angiogenesis. Examination
of the tissue-specific effects of frg1 overexpression in our Xenopus
system has shown that increased levels of FRG1 can account for
the two prominent clinical aspects of FSHD, namely dystrophic
muscle and increased angiogenesis.
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Fig. 4. Transgenic animals with FRE-specific expression of
FRG1 have increased levels of vascular defects. (A) Diagram of
the construct used to make transgenic tadpoles, depicting the
gamma crystalline-EGFP reporter and the HS4 and Fab8 insulator
sequences flanking the X. tropicalis (Xt) proximal frg1 promoter,
which drives expression of the X. tropicalis frg1 cDNA.
(B,D,E) Transgenic animals displayed increased levels of ventral
edema (B) or major vascular abnormalities (white arrow in D)
when compared with non-transgenic controls (E) (red
arrowheads indicate the normal vascular path). (C) Numbers of
transgenic (trans) and non-transgenic embryos (cont) that display
the ventral edema circulation defect or large vascular
abnormalities. The numbers at the top of the bars indicate the
total numbers of animals analyzed. Bars, 1 mm.
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METHODS
Frog husbandry
Adult X. laevis frogs were purchased from Xenopus Express. All
procedures were carried out in accordance with established UIUC
Institutional Animal Care and Use Committee (IACUC)-approved
protocols for animal welfare.
In situ hybridizations, immunohistochemistry and X. laevis FRG1
antibody
In situ hybridizations were carried out as described (Hanel et al.,
2009). Treatment and immunostaining of embryos using the XL
FRG1 antibody were performed as described previously (Hanel et
al., 2009). The previously characterized XL FRG1 rabbit polyclonal
antibody was raised against the peptide EREAKRDDDIPNED and
was produced by GenScript Corp (Hanel et al., 2009).
Sectioning and immunohistochemistry
Leg muscles dissected from froglet and adult frogs were snap
frozen in isopentane, cooled in liquid nitrogen and cryosectioned
into 10 μm sections. FRG1 immunostaining gave identical staining
after acetone or formaldehyde fixation. Double staining with
FRG1 and rhodamine-labeled Griffonia simplicifolia lectin I (GSL
I) (Vector laboratories) was performed on sections fixed in acetone
for 5 minutes. Slides were blocked in 2% donkey serum and 1%
BSA. The XL FRG1 antibody was used at a dilution of 1/100 and
detected with secondary donkey anti-rabbit fluorescein (1/100).
After washing, GSL I was applied to slides at a concentration of
40 μg/ml and incubated for 1 hour. For peptide competition
experiments, sections were treated with 0.5% Triton X for 5
minutes, followed by fixation in 10% formaldehyde in PBS for 10
minutes. Slides were blocked in 2% donkey serum, 1% BSA, 0.1%
Triton X, 0.05% Tween 20. XL FRG1 antibody was incubated with,
and without, a 50-fold excess of peptide at 37°C for 2 hours,
followed by 16 hours at 4°C with rocking. The antibody-peptide
mixture was centrifuged at 20,000 g for 15 minutes and the
supernatant was diluted in the blocking solution and used for
immunostaining.
Transgenic construct cloning
All PCR products were initially cloned into pGEM-T easy vectors
(Promega) and sequenced. All PCR primers are listed in the
supplementary material Table S1. The X. tropicalis frg1 proximal
regulatory element (FRE) was amplified by genomic PCR (using
primers 1 and 2). The X. tropicalis frg1 cDNA was amplified from
total RNA by reverse transcriptase (RT)-PCR (using primers 3 and
4) and reamplified (using primers 5 and 6) for cloning.
pCAIN
The pEGFP-N1 (Clontech) vector was digested with AseI and
XhoI, filled in using the Klenow fragment of Escherichia coli DNA
polymerase I and self-ligated. The plasmid was digested with
AflII, filled in using the Klenow fragment and self-ligated. The
chicken β-globin insulator (HS4) (Prioleau et al., 1999) was
amplified by genomic PCR (using primers 7 and 8) from chicken
blood DNA and reamplified using primers 9 and 10, or 11 and
12. The PCR products were digested with EcoRI and SpeI, or
BamHI and XbaI, and cloned by triple ligation into the modified
pEGFP-N1 vector that had been digested with EcoRI and BamHI;
this process was repeated by using primers 13 and 10, or 11 and
14, and cloning into the BamHI–NotI-digested vector, resulting
in pCAIN.
pCAIN FRE-EGFP
FRE was isolated from FRE-pGEM by AseI-BamHI digestion and
ligated into the similarly digested pEGFP-N1 vector. The resulting
vector, FRE-EGFP, was digested with AseI and AflII, and cloned
into similarly cut pCAIN.
pCAIN GC FRE-FRG1
PCR was performed on purified Drosophila genomic DNA using
primers 15 and 16 to produce the Fab8 insulator. This was then
reamplified using primers 17 and 18, and 19 and 20, and cloned
into pCAIN. The gamma crystalline-GFP reporter was cloned from
pCGCG (a gift from Dr Yun-Bo Shi) (Fu et al., 2002). This vector
was then digested with AseI-AflII and ligation was performed with
the similarly digested FRE-FRG1 vector.
Xenopus transgenesis
Xenopus transgenesis was carried out essentially as described
previously (Kroll and Amaya, 1996; Wuebbles and Jones, 2007);
dmm.biologists.org272
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Clinical issue
Facioscapulohumeral muscular dystrophy (FSHD) is the third most common
myopathy, afflicting approximately one out of 20,000 people worldwide. The
most characteristic symptom is a progressive atrophy of facial, shoulder and
upper arm muscles. Additionally, over half of FSHD patients have abnormal
blood vessels in the back of the eye, which causes vision problems in some
patients.
Over 95% of FSHD cases carry a genetic abnormality within a series of DNA
repeats at chromosome 4q35. Although the unaffected population contains
between 11 and 150 copies of this DNA repeat (named D4Z4), FSHD patients
have deletions resulting in between one and ten D4Z4 repeats. This mutation
is not in a known protein-encoding gene, thus these deletions are expected to
disrupt the normal regulation of gene expression. However, there is little
agreement regarding which gene or genes are misregulated in FSHD, thus
complicating the creation of appropriate FSHD animal models, and hindering
advances in understanding and treating this disease. Previous studies
demonstrate that altered expression of FRG1disrupts the musculature in
developing Xenopus laevis, thus supporting a role for FRG1 in FSHD pathology.
Results
In this study, the spatiotemporal expression of FRG1 is analyzed during
Xenopus development, revealing prominent expression in the vasculature. The
authors show that FRG1 is required for the growth of new blood vessels from
pre-existing vessels, but is not needed for spontaneous blood vessel
formation. Conversely, increasing FRG1 levels promotes angiogenesis and
disrupts the organization of the developing vasculature. Thus, normal levels
and patterns of FRG1 expression are crucial for proper vascularization.
Implications and future directions
This study, combined with previous work analyzing the effect of FRG1 on the
developing musculature, demonstrates that FRG1 affects the skeletal
musculature and the vasculature when its expression levels are altered in an
animal model. Thus, FRG1 expression is a causal factor in FSHD pathology.
Prominent expression of FRG1 in the vasculature suggests that future FSHD
research should examine vascular cell types and tissue, as well as skeletal
muscle.
doi:10.1242/dmm.003061
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however, the sperm nuclei were not digested with restriction
enzymes. Plasmids were linearized, purified and incubated (100 ng
per experiment) with sperm nuclei for 5 minutes. Xenopus egg
extract (10 μl) and 20 μl of sperm dilution buffer (SDB; 250 mM
sucrose, 75 mM KCl, 0.5 mM spermidine, 0.2 mM spermine) were
mixed and incubated at 65°C for 5 minutes, then centrifuged at
16,000 g for 3 minutes to remove the precipitate. The soluble
fraction (6 μl) was diluted to 22 μl with SDB plus 10 mM of MgCl2,
then added to the nuclei-sperm mix and incubated for 15 minutes
at room temperature. The swollen nuclei were added to 170 μl of
SDB and used for microinjection at a rate of 0.586 μl/minute using
a microliter syringe pump (Harvard Apparatus).
Probe constructs
The PCRs for cloning used the Triplemaster polymerase enzyme
mixture (Eppendoerf); the RT-PCRs used the Superscript III HiFi
one-step RT-PCR kit (Invitrogen); and restriction enzymes were
purchased from New England Biolabs. All oligonucleotide primers
are listed in supplementary material Table S1. Total RNA was
extracted from the ovaries of X. laevis and X. tropicalis frogs with
Trizol (Invitrogen), as per the manufacturer’s instructions, and used
for RT-PCR (with primers 21 and 22 for dab2, 23 and 24 for msr,
and 25 and 26 for egfp) to produce cDNA. All products were cloned
into pGEM T-Easy vectors (Promega) and sequenced.
RNA and morpholino microinjections
Morpholino and mRNA injections were performed as described
previously (Hanel et al., 2009).
Vascular labeling in tadpoles
Fluorescein-labeled dextran (9.2 nl) was injected into the heart of
stage 46 transgenic and non-transgenic tadpoles, incubated for
30 minutes at 16°C, and visualized using a Leica dissecting
microscope.
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